From: Therapeutic strategies in RET gene rearranged non-small cell lung cancer
Agent | ORR (%) | mPFS (mo) | mOS (mo) | Common Gr 3 or 4 AEs | Refs |
---|---|---|---|---|---|
Selpercatinib (first line) | 85 | NR | Hypertension, elevated AST, ALT, | [27] | |
Pralsetinib (first line) | 73 | NR | Anemia, hypertension, Neutropenia, | [32] | |
Vandetanib | 18 | 4.5 | 11.6 | Hypertension, diarrhea, rash, dry skin, QT prolongation | [41] |
Cabozantinib | 28 | 5.5 | 9.9 | Elevated lipase, ALT, AST, thrombocytopenia, hypophosphatemia | [42] |
CPI (Nivolumab or Pembrolizumab) | 12.7 | 3.4 (95% CI 1.7–6.2) | 18.4 (95% CI 7.0–NR) | NA | [8] |
Platinum-Pemetrexed (first line) | 50 | 9.2 | 26.4 | NA | [37] |